Study on fungal infection prevention with liposomal amphotericin B
Treatments studied
Part of Infections clinical trials.
This trial looks at how a specific antifungal medicine, called liposomal amphotericin B, given over a longer period, helps prevent serious fungal infections in people undergoing treatment for cancer or receiving a stem cell transplant. It may be an option if you are at high risk for these infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are receiving chemotherapy (either for the first time or for a relapse) or a stem cell transplant from a donor (allo-HSCT).
- You have not had a previous fungal infection that required treatment (this is for primary prevention, not secondary).
- You have no known allergies or other reasons why you cannot take liposomal amphotericin B.
- You are considered at high risk for developing a serious fungal infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
This trial tests amphotericin B (an antifungal medication) in patients with blood cancers who develop a fungal infection despite already taking antifungal preventive medicine. The study aims to see if this medication can treat these hard-to-treat infections.
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
This trial studies how the body processes the antifungal drug liposomal amphotericin B (L-AmB) in patients on ECMO (a heart-lung machine). The goal is to find the right dose for treating invasive fungal infections in ICU patients who need ECMO support.
This study measures how the body processes a common antifungal medicine (liposomal amphotericin B) in patients who have a serious fungal infection and are also undergoing plasma exchange—a treatment that filters and cleans the blood. Understanding these drug levels may help doctors give better doses.
This trial tests a combination of antifungal medicines (liposomal amphotericin B and either isavuconazole or posaconazole) for people with blood cancers who develop a fungal infection despite taking preventive antifungal drugs. It aims to find a better treatment for these difficult infections.
Hear when a new Invasive Fungal Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.